IDEXX Laboratories, Inc.
IDXXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeIDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. With a market capitalization of $42.18B, it sits in large-cap territory. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Market Cap
$42.18B
Beta
1.54
P/E (TTM)
37.60
P/E (Fwd)
31.98
EPS (TTM)
$14.24
EPS (Fwd)
$16.74
ROE
74.2%
ROA
27.1%
Cash
$196.9M
Total Debt
$1.10B
Free CF
$909.4M
52W Change
-18.3%
Annual Financials
Cash vs Debt
Where IDXX stands vs its 150-day and 200-day moving averages
As of the August 19, 2026 close, IDXX finished 5.82% below its 150-day moving average ($587.52) and 10.27% below its 200-day moving average ($616.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IDXX overbought or oversold?
At the August 19, 2026 close, IDXX's RSI(14) was 43.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $196.9M in cash, though total debt stands at $1.10B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $909.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 74.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 27.1% further supports the picture of efficient asset utilization. Revenue has grown from $3.37B (2022) to $4.30B (2025), reflecting a 28% increase over the period.
IDEXX Laboratories, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. IDEXX Laboratories, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing IDXX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.